News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,172 Results
Type
Article (41395)
Company Profile (297)
Press Release (684469)
Multimedia
Podcasts (90)
Webinars (17)
Section
Business (205630)
Career Advice (2039)
Deals (35660)
Drug Delivery (116)
Drug Development (81608)
Employer Resources (173)
FDA (16458)
Job Trends (15006)
News (347761)
Policy (32850)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2591)
Accelerated approval (37)
Adcomms (24)
Allergies (149)
Alliances (49922)
ALS (176)
Alzheimer's disease (1689)
Antibody-drug conjugate (ADC) (329)
Approvals (16736)
Artificial intelligence (542)
Autoimmune disease (166)
Automation (44)
Bankruptcy (364)
Best Places to Work (11658)
BIOSECURE Act (21)
Biosimilars (195)
Biotechnology (190)
Bladder cancer (165)
Brain cancer (58)
Breast cancer (651)
Cancer (4965)
Cardiovascular disease (410)
Career advice (1725)
Career pathing (37)
CAR-T (288)
CDC (50)
Celiac Disease (2)
Cell therapy (766)
Cervical cancer (37)
Clinical research (69870)
Collaboration (1774)
Company closure (4)
Compensation (1184)
Complete response letters (58)
COVID-19 (2732)
CRISPR (96)
C-suite (891)
Cystic fibrosis (145)
Data (6435)
Decentralized trials (2)
Denatured (30)
Depression (138)
Diabetes (511)
Diagnostics (6760)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (265)
Drug pricing (190)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (90611)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (118201)
Executive appointments (999)
FDA (19662)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1521)
Gene editing (207)
Generative AI (44)
Gene therapy (617)
GLP-1 (983)
Government (4691)
Grass and pollen (6)
Guidances (385)
Healthcare (18908)
HIV (68)
Huntington's disease (48)
IgA nephropathy (84)
Immunology and inflammation (262)
Immuno-oncology (67)
Indications (127)
Infectious disease (3020)
Inflammatory bowel disease (200)
Inflation Reduction Act (16)
Influenza (124)
Intellectual property (258)
Interviews (316)
IPO (16678)
IRA (52)
Job creations (3678)
Job search strategy (1440)
JPM (58)
Kidney cancer (18)
Labor market (87)
Layoffs (557)
Leadership (34)
Legal (7987)
Liver cancer (92)
Longevity (17)
Lung cancer (669)
Lymphoma (384)
Machine learning (45)
Management (59)
Manufacturing (828)
MASH (166)
Medical device (13804)
Medtech (13864)
Mergers & acquisitions (20068)
Metabolic disorders (1298)
mRNA (161)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (333)
Neuropsychiatric disorders (90)
Neuroscience (2967)
Neurotech (1)
NextGen: Class of 2026 (6556)
Non-profit (4527)
Now hiring (69)
Obesity (611)
Opinion (271)
Ovarian cancer (169)
Pain (206)
Pancreatic cancer (240)
Parkinson's disease (291)
Partnered (35)
Patents (516)
Patient recruitment (521)
Peanut (59)
People (59322)
Pharmaceutical (66)
Pharmacy benefit managers (30)
Phase 1 (21800)
Phase 2 (30751)
Phase 3 (22906)
Pipeline (5773)
Policy (296)
Postmarket research (2565)
Preclinical (9251)
Press Release (64)
Prostate cancer (253)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (885)
Real estate (6002)
Recruiting (70)
Regulatory (24705)
Reports (53)
Research institute (2402)
Resumes & cover letters (354)
Rett syndrome (29)
RNA editing (19)
RSV (81)
Schizophrenia (150)
Series A (257)
Series B (194)
Service/supplier (13)
Sickle cell disease (101)
Special edition (23)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3673)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (58)
Vaccines (1024)
Venture capital (91)
Weight loss (392)
Women's health (98)
Worklife (19)
Date
Today (39)
Last 7 days (879)
Last 30 days (2821)
Last 365 days (29999)
2026 (4884)
2025 (30331)
2024 (35329)
2023 (40179)
2022 (51288)
2021 (55834)
2020 (54153)
2019 (46641)
2018 (35123)
2017 (32221)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (740)
Alabama (86)
Alaska (7)
Arizona (315)
Arkansas (13)
Asia (39490)
Australia (6471)
California (11669)
Canada (3357)
China (1125)
Colorado (490)
Connecticut (489)
Delaware (342)
Europe (85261)
Florida (1746)
Georgia (370)
Hawaii (3)
Idaho (62)
Illinois (889)
India (71)
Indiana (538)
Iowa (22)
Japan (442)
Kansas (128)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1415)
Massachusetts (8324)
Michigan (335)
Minnesota (637)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (125)
New Hampshire (81)
New Jersey (3086)
New Mexico (28)
New York (3055)
North Carolina (1484)
North Dakota (8)
Northern California (5729)
Ohio (348)
Oklahoma (21)
Oregon (42)
Pennsylvania (2344)
Puerto Rico (24)
Rhode Island (49)
South America (1111)
South Carolina (68)
South Dakota (1)
Southern California (4548)
Tennessee (180)
Texas (1797)
United States (41213)
Utah (350)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (942)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
726,172 Results for "remegen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Cancer
JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
January 14, 2026
·
2 min read
·
Heather McKenzie
Press Releases
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
January 12, 2026
·
6 min read
Press Releases
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - February 9, 2026
February 10, 2026
·
1 min read
Press Releases
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
June 25, 2025
·
7 min read
Press Releases
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
February 26, 2026
·
7 min read
Press Releases
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
January 26, 2026
·
5 min read
Press Releases
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
January 9, 2026
·
3 min read
Press Releases
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
February 12, 2026
·
6 min read
Press Releases
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
January 27, 2026
·
5 min read
1 of 72,618
Next
